Ensayos clínicos

Inclusion Criteria:

• Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem.
• Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority.
• Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
  • All cancer cases with an ICD-O histologic behavior code of two “2” (carcinoma in situ) or three “3” (malignant);
  • All neoplastic lesions of the central nervous system regardless of behavior; i.e., benign, borderline or malignant;
• The following other benign/ borderline conditions:  
  • Mesoblastic nephroma;
  • Teratomas (mature and immature types);
  • Myeloproliferative diseases including transient myeloproliferative disease;
  • Langerhans cell histiocytosis;
  • Lymphoproliferative diseases;
  • Desmoid tumors;
  • Gonadal stromal cell tumors.
• Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
• All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study. Parents will be asked to sign a separate consent for their own biospecimen submission.
• If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow. Consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1.